Novo Nordisk's stock has fallen about 70%, trading at roughly 10 times trailing earnings, presenting a buying opportunity. Despite setbacks in pricing and clinical trials, the company's promising drug pipeline, including high-dose Wegovy and other candidates, positions it favorably against competitors like Eli Lilly. The stable revenue outlook and potential price-to-earnings re-rating support expectations of mid-teens annualized returns through 2030. Risks include further clinical failures and government pricing actions, but current market pessimism may undervalue the company's long-term potential.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
